We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mitochondrial Peptide Protects Brain from Age-Related Dementias

By LabMedica International staff writers
Posted on 04 Oct 2018
A recent study contributed new evidence that strengthens the hypothesis that the peptide humanin protects the brain against the development of Alzheimer's disease and other age-related dementias.

Humanin (HN) is a 24-amino acid mitochondria-associated peptide. More...
Since its initial discovery more than 10 years ago, a role for HN has been reported in many biological processes such as apoptosis, cell survival, substrate metabolism, inflammatory response, and response to stressors such as oxidative stress, ischemia, and starvation. Mounting evidence has suggested that HN and other mitochondrial derived peptides play a role in several age-related conditions including neurodegenerative disease.

In light of findings that HN levels decrease with age, investigators at the University of Southern California (Los Angeles, USA) sought to confirm that humanin played an important function in the aging process and the onset of age-related diseases.

To this end, they used a mitochondrial GWAS (genome-wide association study) to identify a specific single-nucleotide polymorphism (SNP) in the humanin-coding region of the mitochondrial genome that was associated with a 14% decrease in circulating humanin levels. In a large, independent cohort, consisting of a nationally representative sample of older adults, the investigators found that this SNP was associated with accelerated cognitive aging; supporting the concept that humanin is an important factor in cognitive aging.

The investigators further reported in the September 21, 2018, online edition of the journal Scientific Reports that mice injected with humanin experienced a delay in cognitive decline associated with aging.

"Because of the beneficial effects of humanin, a decrease in circulating levels could lead to an increase in several different diseases of aging, particularly in dementia," said senior author Dr. Pinchas Cohen, professor of gerontology, medicine, and biological sciences at the University of Southern California. "This provides the first evidence that a variation in the sequence of a mitochondrial peptide is associated with a change in the level of peptides and the first conclusive demonstration that mitochondrial peptides are encoded in and regulated through mitochondrial DNA."

Related Links:
University of Southern California


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Biochemical Analyzer
iBC 900
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.